Answers are grounded in this paper and cite their sources.
This study shows that LND for patients with lymph node metastases of cSCC leads to a 5-year DSS of 52%. After LND, approximately one-third of the patients develop recurrent disease (locoregional and/or distant), which underscores the need for better systemic treatment options for locally advanced cSCC. The size of the primary tumor, more than one positive lymph node, and immunosuppression are independent predictors for risk of recurrence and disease-specific survival after LND for cSCC.
No takes yet. Share an insight, caveat, or question.
Veld et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: